Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Gregory Berger

Gregory Berger

Technical Lead Industrialisation Scientist, Cell & Gene Therapy Catapult

Greg has been at the cell and Gene Therapy Catapult since early 2017 and brings a wealth expertise in viral vector/cell line development, vector production in bioreactors and development of appropriate analytical tools for characterisation and functionality assessment. Greg obtained his PhD in Virology and Immunology from the Ecole Normale Superieure de Lyon (ENS Lyon) in France, focussing upon the development of new Lentiviral vectors for the development of Dendritic cell-based immunotherapy. He then joined the department of Immunobiology and Infectious Disease at King’s College London as a post-doctoral researcher where his work focussed predominantly on viral vector integration and immune cell dysfunction upon transduction. At CGTC, Greg is currently working with the process and analytical team to address the current challenges regarding viral vector manufacturing.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd